Drug Name: Rystiggo
Indications: To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive.
Active Ingredient: Rozanolixizumab-noli
Company: UCB, Inc
Approval Date: 6/26/2023
More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761286s000lbl.pdf